#USA #Boston #Field Medical #FieldForce #AF Symposium

Field Medical Showcases Innovative Data at AF Symposium 2026

Field Medical, Inc., a pioneering company in clinical-stage medical technology, has recently emerged as a key player in the field of cardiac care by presenting groundbreaking trial data on their pulsed field ablation (PFA) solutions. This unveiling took place during the highly anticipated AF Symposium 2026, which ran from February 5 to 7 in Boston.

The presentation focused on the results of the Field PULSE trial, the first of its kind involving human participants, which demonstrated the effectiveness of the FieldForce™ Ablation System. This advanced system employs a unique high-voltage pulsed field waveform that facilitates rapid ablation of the heart's tissue, pivotal for addressing complex cardiac arrhythmias. The ability to deliver instantaneous point-by-point energy without necessitating prolonged contact with the catheter promises to transform how these procedures are performed.

Dr. Vivek Y. Reddy, who served as the principal investigator for the Field PULSE trial and is an established electrophysiologist at Mount Sinai, highlighted the innovative advantages of this approach. He explained that the new technique allows for efficient point-by-point ablation and the creation of personalized lesion sets while maintaining the flexibility that physicians rely on during focal ablation procedures.

Key Findings of the Field PULSE Trial

The findings presented at the AF Symposium 2026 showcased several significant outcomes from the trial:

• - Instantaneous Ablation Delivery: The system successfully created lesions in less than 200 milliseconds, which represents a remarkable advancement in procedural efficiency.
• - Speed of Procedures: The median time recorded for bilateral pulmonary vein isolation (PVI) was just 12.5 minutes, with some cases completed in an astounding 7.7 minutes.
• - Durability of Procedures: Assessments revealed an impressive improvement in PVI durability over time, with 94.2% success by vein and 84.6% success by patient across the study.

Importantly, the safety outcomes were reassuring, with no device-related serious adverse events reported. Additionally, among the patients assessed via brain MRI, no silent cerebral lesions were observed, underscoring the relative safety of the procedure as compared to traditional methods.

Challenges Overcome by PFA Technology

This innovative research extends the growing body of evidence supporting Field Medical's high-voltage focal PFA approach, particularly in the context of treating atrial fibrillation (AF). This method builds upon past successes related to ventricular tachycardia (VT) treatments, demonstrating the versatility of the Field Force ablation platform across various cardiac chambers. Dr. Steven Mickelsen, the founder and chief technology officer of Field Medical, emphasized the technology's foundation in addressing the critical limitations of existing ablation methods. The goal is to minimize dependency on prolonged catheter stability and the effects induced by cardiac motion.

The presentation at the AF Symposium not only shed light on this innovative technology, but it also placed Field Medical on the forefront of cardiac treatment solutions. Attendees were invited to engage with the company during a specialized scientific session on the biophysics of PFA, where discussions revolved around maximizing lesion depth with the high-voltage waveform. This adds a critical layer to the evolving conversational landscape in cardiac health management, primarily focusing on increasing precision and efficiency

For interested stakeholders in the medical community, further insights and data from Field Medical can be found on their official website, providing a gateway into the future of medical technology in treating cardiac arrhythmias. As the field of healthcare continues to evolve, innovations such as those presented at the AF Symposium have the potential to redefine standards of care significantly, enhancing patient outcomes and transforming the medical landscape for heart-related conditions.

About Field Medical
Field Medical, Inc., founded in 2022, is dedicated to pioneering advancements in pulsed field ablation technology for complex cardiac arrhythmias. Its flagship FieldForce Ablation System showcases cutting-edge engineering designed to improve treatment efficacy in both atrial and ventricular cases. The firm is committed to the ongoing research and development required to maintain its position as a leader in cardiac medical technologies, ensuring that patients receive state-of-the-art care as part of their treatment plans.